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Abstract 
Background 
Type 2 diabetes (T2D) and raised blood lipids are associated with the use of antipsychotics, not least 
clozapine.   
Aims 
To describe the prevalence of high blood glucose levels, T2D and dyslipidemia in association with the use of 
clozapine or other antipsychotics in patients with schizophrenia in Iceland. 
Method 
We identified 188 patients treated with clozapine and 395 patients never treated with clozapine by searching 
the electronic health records of Landspitali, the National University Hospital.  The comparison group 
consisted of Icelandic population controls.  We obtained data on blood glucose, HbA1c and blood lipid 
levels from these health records. 
Results 
The prevalence of T2D was 14.3% in the clozapine group, where the average age was 51.2 years, and 13.7% 
in the never-on-clozapine group where the average age was 58.6 years. Males on clozapine were 2.3 times 
more likely and females 4.4 times more likely to have developed T2D than controls from an age-adjusted 
Icelandic cohort while males on other antipsychotics were 1.5 times more likely and females 2.3 times as 
likely to have T2D.  Having ever been measured with a high blood sugar level, over 13 mmol/l, was strongly 
associated with T2D. Only one case of ketoacidosis was identified.  Triglyceride levels were significantly 
higher in both treatment groups compared to controls in the age-adjusted Icelandic cohort.  
Conclusions 
Clinicians must take active steps to reduce the risk of T2D and raised triglycerides in patients with 
schizophrenia.  Antipsychotics were associated with a greater risk of T2D developing in females compared 
to males. 
Keywords: schizophrenia, clozapine, diabetes, dyslipidemia, metabolic 
Running title:  Diabetes and dyslipidemia with antipsychotic drugs  
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Background 
Second generation antipsychotics (SGA) have been widely reported to increase the risk of T2D, 
obesity and dyslipidemia during the treatment of psychotic disorders such as schizophrenia (1).   
Most antipsychotics have been associated with weight gain, at least in some patient populations.  
Olanzapine and clozapine have the highest risk of weight gain (1). Ziprasidone, aripiprazole and amisulpride 
have the lowest reported risk of weight gain but risperidone and quetiapine are intermediate in this regard 
(1). Obesity is the main modifiable risk factor for T2D and 80% of patients are overweight at diagnosis (2).  
Females may be at higher risk for weight gain (3).  Some patients are particularly prone to weight gain and it 
has been reported that a common variant near the melanocortin 4 receptor gene is associated with severe 
SGA-associated weight gain (4).  It has also been reported that when switching from an antipsychotic with a 
high risk for weight gain to an antipsychotic with a less risk for weight gain, patients find it easier to lose 
weight in due course (5).   
Metabolic syndrome has been shown to be more common with patients treated with clozapine 
(51.9%) than with other antipsychotics in schizophrenia (32.5%) (6).  In the Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) study, the proportion of males with metabolic syndrome was 36.6% but 
54.2% for females (7).  In an Icelandic study of patients with schizophrenia with a mean age of 50 years the 
prevalence of metabolic syndrome was found to be 57% compared to 14% in the general population (8).  In 
the same study the prevalence of T2D was 15%. 
The risk of T2D is not the same for all second generation antipsychotics.  Aripiprazole and 
ziprasidone are associated with the lowest risk and some studies report no added risk for patients on these 
drugs (9-11).  The risk for T2D has been reported to be dose dependent for some antipsychotics such as 
olanzapine, risperidone and quetiapine (10).   
Patients treated with antipsychotics have an estimated 10 times the risk of developing ketoacidosis 
compared to the normal population (12).  Increased risk of ketoacidosis during clozapine treatment has been 
documented in case reports (13).   
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Dyslipidemia, which is a well known risk factor for coronary artery disease is characterized by 
elevated triglycerides, high cholesterol, high levels of low density lipoprotein (LDL) and low levels of high 
density lipoprotein (HDL) (14).  Clozapine and olanzapine have been associated with an increase in 
cholesterol and triglyceride levels in patients with schizophrenia (15-18).  These drugs have also been shown 
to decrease HDL-cholesterol (16).  Risperidone has also been associated with increased triglyceride levels 
(16).  Other antipsychotics like amisulpride and ziprasidone have been reported to have a more favorable 
effect on blood lipid profiles and may therefore be preferable for patients who have developed the metabolic 
syndrome (18). 
Life expectancy in schizophrenia is reduced by more than 20 years, mainly due to relatively poor 
physical health, although a high risk for suicide also has an impact (19).  Antipsychotic drug use in 
schizophrenia is associated with higher life expectancy even though antipsychotics are associated with 
metabolic side effects (19). Clozapine has been reported to have more adverse effects than other 
antipsychotics but there is evidence that clozapine reduces the risk of suicide as well as overall mortality 
compared to other antipsychotics (19).  The risk of death from cardiovascular disease for patients on 
clozapine may be dependent on genetic makeup, diet and social factors because the rate of death from 
cardiovascular disease in Hispanic and African-American patients receiving clozapine has been reported to 
be 4.3 and 11.5 times the rate in Caucasians, respectively (17).   
Aims 
The aim of this study is to analyze the prevalence of diabetes and dyslipidemia in a well-described 
sample of Icelandic schizophrenia patients on clozapine as well as patients with schizophrenia who have 
never been on clozapine. In order to assess the standardized morbidity ratio of diabetes and dyslipidemia for 
both groups the results will be contrasted with prevalence figures based on Icelandic population cohorts.   
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Methods 
Study population 
The study population has been described in a previous article by the same authors (20).  The study is 
a part of an ongoing study of psychotic disorders in the Department of Psychiatry at Landspitali University 
Hospital (LUH), focusing on patients with schizophrenia and bipolar disorder.  In this study we looked at 
patients in the LUH cohort who were alive on 1.1.2003 and who had a confirmed diagnosis of schizophrenia 
according to the “Schedules for Affective Disorder and Schizophrenia-Lifetime version” (SADS-L) (21).  In 
total there were 611 patients who met the criteria.  All participants gave written informed consent.  We 
identified in this way 201 patients with schizophrenia who had used clozapine and 410 patients with 
schizophrenia who had never used clozapine but been treated with other antipsychotics.    
 
Figure 1.  Description of study cohort in the study period of 1.1.1998 – 21.11.2014 
 
Metabolic disorders 
T2D was diagnosed if the patients had a formal diagnosis of T2D, HbA1C >=6.5% on two separate 
occasions or two measurements of fasting plasma glucose over 12.6 mg/l (7.0 mmol/l).  The patient’s 
primary physician was contacted if additional blood samples were needed to assess if the patients had 
developed T2D.  High risk of T2D was labelled if the last measurement of HbA1c was in the range 6.0% to 
6.4%.  Ketoacidosis was diagnosed if a clinical diagnosis of ketoacidosis could be confirmed.  In accordance 
with the ATP-III guidelines we defined LDL in the range 160-189mg/dl (4.13-4.89 mmol/l) as high LDL 
and LDL over 190mg/dl (4.90 mmol/l) as very high (14).  Total cholesterol over 200mm/dl (5.17 mmol/l) 
was defined as high. Triglycerides between 200-499mg/dl (2.56-5.63 mmol/l) were defined as high and 
triglycerides over 500mg/dl (5.65 mmol/l) as very high.  When analyzing statin use while patients were 
taking clozapine, we used the last known medication regimen stated in the medical notes before the end of 
follow-up or the date that the patient discontinued clozapine.   
A keyword search in the EHR was done, to find medical notes where the metabolic disorders were 
mentioned.  For diabetes we looked for “diabetes”, “sykursýki”, “metformin”, “glucophage” and “T2D”.  
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For Ketoacidosis we looked for “ketoacidos” and “ketona”.  For dyslipidemia the blood lipid measurements 
in the blood test database were analyzed.  All blood measurements of:  HbA1c, glucose, total cholesterol, 
LDL cholesterol, HDL cholesterol and triglycerides were collected electronically via the EHR.  When 
assessing blood lipids the latest measurements of blood lipids were used.  For patients on clozapine we used 
the latest blood measurements while the patient had been receiving clozapine.   
 
Statistical analysis 
Statistical analyses were performed with STATA, version 13.  A Cox proportional hazard model was 
used to assess the association of blood sugar values over 13 mm/l with “average time at risk”, “clozapine 
ever used” and “T2D at the end of follow up”.  Time at risk for patients on clozapine was defined as the start 
of clozapine treatment or the start of the study period if the patients had started clozapine treatment before 
the onset of the study period, until one of the following end points was reached: a measurement of blood 
sugar value over 13 mm/l, end of the study period, patient died or when the patient discontinued clozapine 
treatment.  Time at risk for patients never on clozapine was defined as the onset of the study period, until 
one of the following end points was reached: a measurement of blood sugar value over 13 mm/l, end of the 
study period or when the patient died.  We tested for the proportional hazards assumption using the estat 
phtest in STATA. 
The prevalence of T2D and blood lipid levels were compared to a population of Icelanders using data 
from the Icelandic National Heart Association making use both of data from the AGES (22) and the 
REFINE (Risk Evaluation For INfarct Estimates) studies.  The prevalence of T2D and blood lipid levels 
were calculated for men and women by age ranges of five years from 25 to 90.  The prevalence of T2D and 
blood lipid levels in different age ranges of the Icelandic population group was used to calculate the 
expected prevalence of T2D and blood lipid levels.  This comparison indicated what prevalence of T2D and 
lipid levels could be expected if comparable age groups were examined in the general population.    
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Results 
Prevalence of diabetes in patients with schizophrenia 
The observed prevalence of T2D was 14.3% in the clozapine group, where the average age was 51.2 
years, whereas the observed prevalence of T2D was 13.7% in the never-on-clozapine group where the 
average age was 58.6 years.  Table 1 describes the prevalence of diabetes in the cohort in more detail.  The 
age adjusted difference of T2D for the groups is shown in table 2.    
In the clozapine group the prevalence of T2D for females was 16.1%, which was higher than for males 
where the proportion of T2D was 13.6% but the difference was not significant (p = 0.32).    
  
Table 1 approximately here 
 
Prevalence of T2D in patients with schizophrenia compared to Icelandic population controls 
Table 2 shows that T2D was more common in patients with schizophrenia than in Icelandic 
population controls adjusted for sex and age.  The standardized morbidity ratio for T2D was highest for 
females on clozapine, 4.4.   
 
Table 2 approximately here 
 
Time from onset of clozapine treatment to diabetes 
The average time from initiation of clozapine treatment to diagnosis of T2D was 7.7 years (SD = 6.7) 
and the median time was 7.3 years in these patients with schizophrenia.  The range of T2D diagnosis was 
from 43 days to 25.3 years.   
 
Ketoacidosis and high blood sugar 
Table 3 demonstrates that not a single case of ketoacidosis was identified in the group of patients on 
clozapine and only a single case in the never-on-clozapine group.  Therefore, the proportion of ketoacidosis 
in the whole group was only 0.2% (1/583).  The highest glucose measurement found in the group of patients 
without T1D or T2D was 15.0 mmol/l.  
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Table 3 approximately here 
 
Table 4 shows that T2D was associated with blood sugar values over 13 mmol/l, in both males and females.  
Clozapine use was not associated with blood sugar values over 13.  Lower age was significantly associated 
with glucose values over 13 mm/l in males but not females.  
 
Table 4 approximately here 
 
 
Blood lipids 
In table 5 the results of blood lipid measurements are presented for 144 patients in the clozapine group and 
258 patients in the never-on-clozapine group.  In the clozapine group 9 patients (6%) had very high levels of 
LDL (over 4.9 mmol/l) and a similar proportion was observed  in the in the never-on-clozapine group, 13 
patients (5%).  In the clozapine group 89 patients (62%) had high levels of total cholesterol (over 5.2 
mmol/l) and 133 (52%) in the never-on-clozapine group.  In the clozapine group 11 patients (8%) had total 
cholesterol below 4 mmol/l, but 34 (13%) in the never-on-clozapine group.   No patient in the never-on-
clozapine group had very high levels of triglycerides (over 5.65 mmol/l) but 5 patients (3%) in the clozapine 
group were observed to have such high levels.     
  
Table 5 approximately here 
 
For medication other than clozapine we had detailed information for 154 patients and of these, 16 were 
using statins (10%) for high cholesterol and one patient (1%) was using a fibrate drug to lower triglycerides 
levels. 
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Conclusions  
The results of this study indicate that treatment with clozapine increases the risk of T2D 4.4 fold for 
females and 2.3 fold for males in patients with schizophrenia.  This gender difference has been reported for 
patients with schizophrenia in a large US study for patients in the Medicare and Medicaid systems (23) but 
the authors have not found this to be reported before for patients on clozapine. High blood sugar (over 13 
mmol/l) was not associated with clozapine use after correcting for TD2 and age in our sample.  Ketoacidosis 
was rare in our sample with only one case identified among 583 patients during follow up lasting on average 
9.2 years for those on clozapine and 13.8 years for those never on clozapine.  That result is similar to what 
was found in a study by the US Veterans Affairs (24) where only 0.2% of patients with schizophrenia were 
hospitalized with ketoacidosis.  Triglyceride levels were elevated both in the clozapine group and in the 
never-on-clozapine group compared to the standard population which is consistent with results described in 
a review article by Newcomer (1).  HDL was lower in the clozapine group compared to the Icelandic 
population but the effects of clozapine on cholesterol are less clear in the literature than the effects on 
triglycerides (1).  The changes in blood lipids are modest and usually do not require treatment with statins in 
primary prevention (14) so more emphasis should be on diagnosing and treating T2D than dyslipidemia.  
Type 2 diabetes 
 Females had a higher standardized morbidity ratio of T2D than males after adjustment for age 
and sex.  The standardized morbidity ratio of T2D for females on clozapine was 4.4 compared to 2.3 in 
males (female/male ratio of 1.9) and for patients with schizophrenia who had never been treated with 
clozapine, it was 2.6 for females and 1.5 for males (female/male ratio of 1.7).  This gender difference for 
T2D in schizophrenia in general has been reported in other studies.  One possible contribution or 
explanation for this sex difference is that clozapine plasma concentration in females has been reported to be 
on average 17% higher in females than in males (25).  A large Medicaid study has reported clozapine to be 
significantly associated with higher rates of T2D than other antipsychotics (26).  In this study of patients 
treated with clozapine, the combined prevalence of T1D, T2D and high risk of T2D was 23.5% for males 
and 32.1% for females. This indicates an overall higher risk of glucose dysregulation for females than for 
males on clozapine treatment. 
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The proportion of patients at a high risk of developing T2D was twice as high in the clozapine group 
as in the never-on-clozapine group, 11.7%, compared to 5.8%.  As one would expect, patients with treatment 
resistant schizophrenia treated with clozapine were more often in contact with the LUH and had more 
frequent measurements of HbA1c done than patients never on clozapine.   
In total there were 27 patients ever treated with clozapine diagnosed with T2D and 16 (59%) of them 
were diagnosed with T2D during clozapine treatment.  Of the other 11 patients 6 (22%) were diagnosed 
before clozapine treatment started and 5 (19%) after clozapine treatment had been discontinued. This 
indicates how complicated it is to assess the causality of clozapine-induced T2D in patients with 
schizophrenia.  In a previous study by the authors on the clozapine group we reported that two thirds of 
patients taking clozapine were taking more than one antipsychotic and used a relatively high WHO defined 
daily dose (DDD), 1.67,  which could also add to the risk of T2D (20).  Patients treated with clozapine are 
the most severely ill patients with schizophrenia and their lifestyle behavior may place them at greater risk 
of T2D than the lifestyles of other patients with the same diagnosis (27).  It is very difficult to control fully 
for these factors, so treatment resistance itself might be an important risk factor for T2D.       
We found 10 patients in the clozapine group who had used metformin to reduce the risk of weight 
gain but did not have diabetes.  That constitutes 5.3% of all patients on clozapine.  Metformin can be used to 
counteract the metabolic side effects of clozapine (28).  This high use of metformin in our cohort without a 
diagnosis of diabetes indicates that diabetes drug use cannot be used reliably as a proxy for the diagnosis of 
T2D in clinical samples. 
 
Ketoacidosis and high blood sugar 
Ketoacidosis was a very rare event in our cohort because only one patient out of 583 had developed 
ketoacidosis and that was a patient who had T1D.  We analyzed with a Cox proportional hazards model if 
high blood glucose (over 13 mmol/l) was associated with clozapine treatment using patients with 
schizophrenia who had never been treated with clozapine for comparison. Clozapine as such was in fact not 
associated with high blood glucose in all the available blood samples but the main risk factor for high blood 
glucose was a diagnosis of diabetes.  Accordingly, the risk of ketoacidosis during antipsychotic treatment 
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seems very small, especially if the patients do not have type 1 diabetes.  In a large study from the US 
Veterans Affairs 0.2% of patients on antipsychotics were hospitalized because of ketoacidosis which is the 
same result as in our study but in that study the risk was highest for patients on clozapine where it was 2% 
which is higher than we observed in our study (24).  
Blood lipids 
Our results show that antipsychotics, especially clozapine, have more adverse effects on triglyceride 
values than on cholesterol as has previously been reported (1, 29).  HDL cholesterol was lower both in the 
clozapine group and in the never-on-clozapine group but that was only statistically significant in the 
clozapine group.   
In the clozapine group 144 out 188 patients (77%) had at least one measurement of blood lipids done 
during clozapine treatment.  Most guidelines on metabolic monitoring for patient on antipsychotics 
recommend that all patients receiving antipsychotic treatment should have blood lipids measured regularly 
(30).  It has been reported that the impact of clinical guidelines on screening and monitoring is minimal to 
poor (30).  One of the issues with the lipid monitoring might be that recent guidelines only support statin 
treatment to lower blood lipids for very high levels of LDL (over 4.90 mmol/l), that is if the patients do not 
have a diagnosis of T2D, atherosclerotic cardiovascular disease or at least a 7.5% risk of developing 
atherosclerotic cardiovascular disease in the next 10 years (14).  In our sample of patients on clozapine, 
where the average age was 51.2 years, only 6% of patients had LDL levels over 4.9 mmol/l.  Recent meta-
analyses for statin use in primary prevention do report reduced total mortality (31, 32).  The proportion of 
patients using statins in our clozapine group was 10% which is the same ratio as in a Danish cohort study 
from 2007 on patients with schizophrenia treated with clozapine (33).  In our sample the LDL and 
cholesterol was essentially the same in the clozapine group, the never-on-clozapine group and in the age and 
sex matched Icelandic population controls.  Screening in the schizophrenia groups would therefore probably 
not support more statin treatment than screening the Icelandic population.  It is therefore unlikely that a 
young patient diagnosed with schizophrenia, who has neither diabetes nor atherosclerotic cardiovascular 
disease will have statins prescribed.      
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There are some limitations to this study.  It is a retrospective comparative analysis of patients that 
have been treated at a national university hospital so the results may not generalize fully to patients with less 
severe forms of schizophrenia who are not in contact with mental health services. The patients on clozapine 
were significantly younger (51.2 years) than those never treated with clozapine (58.1 years).  By definition 
patients treated with clozapine are suffering from a more severe and a more treatment-resistant form of 
schizophrenia so the clozapine is not the only difference between these two groups.  The strengths of the 
study include the screening availability of electronic health records over long perionds, full access to all 
patient records at LUH over two decades in a hospital where over 90% of all patients with schizophrenia 
have been treated for the past decades.  
 Clinicians need to be aware of the risk of T2D developing for patients with schizophrenia, in 
particular for females on clozapine treatment.  Regular measurements of fasting glucose and HbA1c should 
be done, at least once a year.  There is less evidence to support annual measurements of blood lipids, 
especially for patients that are on a stable antipsychotic treatment unless blood lipids are elevated or the 
patient has a diagnosis of atherosclerotic cardiovascular disease or T2D.  As patients with schizophrenia are 
at a very high risk of developing atherosclerotic cardiovascular disease (34) more research is needed to 
assess whether statins should be used more for primary prevention in patients with schizophrenia.  
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Figure legends 
 
Figure 1.  Description of study cohort in the study period of 1.1.1998 – 21.11.2014 
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Tables: 
Table 1.  Diabetes in patients with schizophrenia treated with clozapine and those never treated with clozapine 
    Clozapine Never-on-clozapine 
    
Male (n = 
132) 
Female (n = 
56) 
Male (n = 
245) 
Female (n = 
150) 
Patients with type 2 diabetes (T2D) 18 9 31 23 
  T2D diagnosed before clozapine treatment 4 2 - - 
  T2D diagnosed during clozapine treatment 11 5 - - 
  
T2D diagnosed after discontinuation of clozapine 
treatment 3 2 - - 
Patients with type 1 diabetes (T1D)   1 0 2 0 
Patients with  of T1D and T2D   19 9 33 23 
Patients with a high risk of T2D (HbA1c in range of 6.0% 
- 6.4%) 13 9 15 8 
Patients with T1D, T2D or a high risk of T2D 32 18 48 31 
Prevalence of  T2D 13.6% 16.1% 12.7% 15.3% 
Prevalence of T1D, T2D or a high risk of T2D 23.5% 32.1% 18.8% 20.7% 
Patients on metformin without a diabetes diagnosis 5 5 - - 
Mean age at end of follow up 50.0 (11.9)* 54.3 (11.4)* 56.7 (14.2)* 61.5 (16.1)* 
Mean follow up period during clozapine treatment in years 9.3 (5.9)* 8.9 (5.6)*     
Mean follow up period in years     14.0 (3.9)* 13.5 (3.8)* 
*Standard deviation         
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Table 2.  Type 2 diabetes in patients with schizophrenia compared to Icelandic population 
controls, age and sex adjusted. 
      Clozapine  Never-on-clozapine 
Male           
  T2D   13.6%   12.7%   
  
Expected T2D from Icelandic 
population 5.8%   8.5%   
  Standardized mortality ratio 2.3   1.5   
  Confidence interval (95%) 1.4-3.5   1.0-2.0   
  P-value   < 0.001   0.029   
Female             
  T2D   16.0%   15.3%   
  
Expected T2D from Icelandic 
population 3.6%   5.5%   
  Standardized mortality ratio 4.4   2.6   
  Confidence interval (95%) 2.1-7.8   1.7-3.7   
  P-value   < 0.001   < 0.001   
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Table 3.  High blood sugar and ketoacidosis in patients with schizophrenia 
  Clozapine Never-on-clozapine 
  n = 188 n = 395 
Highest glucose measurement 
(mmol/l) 
13-
20 
20-
30 
30-
40 40< Ketoacidosis 
13-
20 
20-
30 
30-
40 40< Ketoacidosis 
Glucose status                     
  Type 2 diabetes (n = 81) 7 1 2 0 0 14 12 0 3 0 
  Type 1 diabetes (n = 3) 0 1 0 0 0 1 0 0 0 1 
  High risk of type 2 diabetes (n = 45) 1 0 0 0 0 0 0 0 0 0 
  No glucose dysregulation (n = 454 ) 0 0 0 0 0 9 0 0 0 0 
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Table 4.  Cox proportional hazards model with possible factors 
associated with glucose over 13 mmol/l 
  Haz. Ratio SE 
z-
score 95% CI P-value 
A.  Male with glucose > 13 mmol/l     
Age 0.97 0.01 -2.38 0.94-.99 0.02 
Clozapine 1.03 0.38 0.08 0.50-2.12 0.94 
T2D 18.7 6.54 8.38 9.4-37.1 0.001 > p 
B.  Female with glucose > 13 mmol/l     
Age 1.01 0.02 0.47 0.97-1.05 0.64 
Clozapine 0.62 0.47 -0.63 0.14-2.78 0.53 
T2D 69.2 72.5 4.04 8.86-539 0.001 > p 
A)  n = 377, 39 cases.  B)  n = 206, 15 cases.     
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Table 5.  Blood lipids in patients with schizophrenia both on clozapine and never on clozapine versus expected values 
from Icelandic population controls 
    Clozapine Expected from 
Icelandic 
population 
P-
value 
Never-on-
clozapine 
Expected from 
Icelandic 
population 
P-
value       
Male n = 99     n = 175     
  
Average age at  last blood lipid 
test 47.7 - - 54.4 - - 
  
Average total cholesterol 
(mmol/l) 5.43 5.23 0.28 5.17 5.25 0.58 
  Average LDL (mmol/l) 3.15 3.31 0.27 3.19 3.31 0.36 
  Average total HDL (mmol/l) 1.21 1.31 0.04 1.26 1.33 0.10 
  
Average total triglycerides 
(mmol/l) 2.34 1.36 < 0.01 1.58 1.35 0.04 
Female   n = 45     n = 83     
  
Average age at  last blood lipid 
test 51.9 - - 58.0 - - 
  
Average total cholesterol 
(mmol/l) 5.84 5.35 0.16 5.39 5.49 0.89 
  Average LDL (mmol/l) 3.55 3.22 0.15 3.25 3.32 0.90 
  Average total HDL (mmol/l) 1.40 1.65 0.01 1.40 1.66 0.34 
  
Average total triglycerides 
(mmol/l) 1.95 1.07 < 0.01 1.64 1.13 0.03 
 
 
 
 
